Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir

Abstract

These findings support the use of this effective therapeutic protocol for HDV-3 in patients of non-European ethnicity and suggest a possible 'easy to treat' variant when compared to HDV-1.

Clinical and virological heterogeneity of hepatitis delta in different regions world‐wide: The Hepatitis Delta International Network (HDIN)

“…A focus of future studies with the HDIN database must be to compare different outcomes of antiviral therapy and to determine to what extent patients benefit from reducing HDVRNA levels or suppressing HDV replication to undetectable levels. This will be important as previous reports show that large differences in clinical endpoints can be achieved with antiviral therapy 7,29,[37][38][39]. In this registry, NUC therapy was associated with a higher likelihood to be negative for HDV RNA, which would be consistent with the data ofSoriano et al 41 but in contrast with the recently published data of the HIV Swiss cohort.…”

Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains

“…A sustained virological response is obtained only in 25%‐47% of treated patients, with no additional improvement with nucleos(t)ide analogues . Interestingly, contrary to all previous studies, a recent article on a small cohort of 22 nonrandomized Brazilian patients, all of Native American descent, infected with an HDV‐3 strain reported a prolonged sustained virological response in >95% after 48 weeks of a therapy that associated interferon‐alpha and entecavir . Such results need to be confirmed in larger cohorts, to elucidate the genetic molecular bases, if any, of these observations and with the use of genotype‐specific RNA quantification assays.…”

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

“…11 Interestingly, genotype 3 may also respond better to IFNa. 12 Among these genotypes, genotype 1 has a worldwide distribution whereas genotypes 2 and 4 are seen mainly in the Far East, genotype 3 in northern South America and genotypes 5 to 8 have only been seen in Africa.…”